ECSP066628A - INDOL-O-GLUCOSIDS REPLACED - Google Patents

INDOL-O-GLUCOSIDS REPLACED

Info

Publication number
ECSP066628A
ECSP066628A ECSP066628A ECSP066628A EC SP066628 A ECSP066628 A EC SP066628A EC SP066628 A ECSP066628 A EC SP066628A EC SP066628 A ECSP066628 A EC SP066628A
Authority
EC
Ecuador
Prior art keywords
glucosids
indol
replaced
indole
diabetes
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Maud Urbanski
Mona Patel
Philip Rybczynski
Xiaoyan Zhang
Mary Pat Beavers
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP066628A publication Critical patent/ECSP066628A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen indol-O-glucósidos sustituidos, composiciones que los contienen, y métodos de uso de los mismos, por ejemplo, para el tratamiento de la diabetes y el Síndrome X.Indole-O-substituted glycosides, compositions containing them, and methods of use thereof are described, for example, for the treatment of diabetes and Syndrome X.

ECSP066628 2003-11-12 2006-06-08 INDOL-O-GLUCOSIDS REPLACED ECSP066628A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51915503P 2003-11-12 2003-11-12
US57975804P 2004-06-15 2004-06-15

Publications (1)

Publication Number Publication Date
ECSP066628A true ECSP066628A (en) 2006-10-25

Family

ID=40433444

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP066628 ECSP066628A (en) 2003-11-12 2006-06-08 INDOL-O-GLUCOSIDS REPLACED

Country Status (2)

Country Link
EC (1) ECSP066628A (en)
RS (1) RS20060323A (en)

Also Published As

Publication number Publication date
RS20060323A (en) 2008-08-07

Similar Documents

Publication Publication Date Title
CR8402A (en) INDAZOL-O-GLUCOSIDS SUBSTITUTES
UY28342A1 (en) NEW COMPOUNDS
MY142777A (en) Substituted indole-o-glucosides
UA87991C2 (en) Substituted indole-o-glucosides
UY28572A1 (en) NEW COMPOUNDS
UY28348A1 (en) NEW COMPOUNDS
ECSP099027A (en) ANTI-DLL4 ANTIBODIES AND METHODS THAT USE THEM
ECSP088543A (en) ANTI-OX40L ANTIBODIES AND METHODS THAT USE THEM
ECSP066467A (en) Polymorphic Forms of 3- (4-amino-1-Oxo-1-3 DIhydroisoindole-2-IL) -Piperidin-2,6-Diona
BRPI0312649A2 (en) compounds, pharmaceutical compositions containing them, and processes of use therefor.
HN2002000275A (en) DERIVATIVES OF 1.8 NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
CL2004001069A1 (en) COMPOUNDS DERIVED FROM 1-BENZOIL-ISOQUINOLINAS SUBSTITUTED; PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PROFILAXIS OF TYPE II DIABETES.
BRPI0417684A (en) compound, pharmaceutical composition, and use of a compound
CY1109916T1 (en) Benzimidazolo-thiophene compounds as PLK inhibitors
NI200600290A (en) PIRAZOL DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND USE PROCEDURES
UY27894A1 (en) CINAMIDE DERIVATIVES
CL2007002890A1 (en) Compounds derived from 2-pyridinecarboxamide, glucosinase activator; pharmaceutical composition; and use of the compound for the treatment of diabetes or obesity.
DOP2006000268A (en) ANTIBACTERIAL AGENTS
CR10280A (en) EFGL7 ANTIBODIES AND METHODS OF USE
UY29732A1 (en) BENZOTIAZOLONAS DERIVATIVES, PREPARATION PROCESSES, COMPOSITIONS AND COMBINATIONS CONTAINING THEM AND APPLICATIONS
UY28694A1 (en) NEW COMPOUNDS
CR9391A (en) DERIVATIVES OF INDANIL-PIPERAZINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY27203A1 (en) USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION
BRPI0515721A (en) use of a src kinase inhibitor and a bcr-abl inhibitor, pharmaceutical composition and combination
BRPI0607351A2 (en) methods for treating lymphomas employing a combination of chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody